Intu Diagnostics raised €1.1 million in bridge funding as it develops a decentralized, electricity-free diagnostics platform using handheld cartridges for nucleic-acid amplification and visual readouts. The Leipzig, Germany-based spinout from the Fraunhofer Institute for Cell Therapy and Immunology said it will use the funds to build an intellectual property portfolio, run pilot manufacturing trials, and prepare for a planned seed financing round. The company’s first application targets human papillomavirus testing. Its platform design aims to support at-home and resource-limited deployments, targeting a diagnostics gap where lab access and infrastructure remain bottlenecks for timely infectious disease detection.